Compare Mitsubishi UFJ Financial Group Inc. Common Stock (MUFG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mitsubishi UFJ Financial Group Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Mitsubishi UFJ Financial Group Inc. Common Stock trades at $21.65 (market cap $247.53B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Mitsubishi UFJ Financial Group Inc. Common Stock is far larger — about 33.7× Spyre Therapeutics Inc. Common Stock's market cap, and Mitsubishi UFJ Financial Group Inc. Common Stock pays a 2.46% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mitsubishi UFJ Financial Group Inc. Common Stock for 2 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MUFG | SYRE | |
|---|---|---|
Market Cap | $247.53B | $7.35B |
Volume | 3,196,989 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $24.13 | $108.92 |
52-Week Low | $14.77 | $22.18 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $28.41T | $6.35B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MUFG trades at $22.40, up 0.22% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.45 exceeding the $0.35 estimate. Fundamentals show robust profitability with a 34.22% net income margin and 12.6% ROE, while valuation ratios like a P/E of 14.99 appear reasonable. Recent news highlights a partnership with SkyDrive for eVTOL feasibility studies and positive analyst momentum coverage.
The outlook is supported by earnings momentum and a 100% buy rating from analysts, but risks include a high debt-to-asset ratio of 5.81 and significant negative cash flow trends. Investor sentiment is optimistic due to strong quarterly results and institutional interest, though technical weakness and macroeconomic sensitivity pose near-term challenges.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mitsubishi UFJ Financial Group Inc. Common Stock
Mitsubishi UFJ Financial Group is a Japanese financial services company providing banking, lending, securities, and asset management services. Its businesses serve individuals, companies, and institutions worldwide.
Read more on MUFG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
